SynthesisBMJ open2022

RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis.

Hongli Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.